Rallybio was established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. The founders of the company - Martin Mackay, PhD, Steve Uden, MD, and Jeffrey Fryer, CPA - are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. Rallybio has earned the support of highly-respected investors in the bioscience sector. The Company is based in Farmington, CT, at the University of Connecticut's Technology Incubation Program. For more information, please visit www.rallybio.com.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/26/18 | $37,000,000 | Series A |
5AM Ventures Canaan Partners Connecticut Innovations New Leaf Venture Partners | undisclosed |
| 05/19/20 | $145,000,000 | Series B |
5AM Ventures Canaan Partners Connecticut Innovations F-Prime Capital Partners Fairview Capital Mitsui & Co New Leaf Venture Partners Pivotal bioVenture Partners Solasta Ventures Tekla Capital Management The Rise Fund Viking Global Investors | undisclosed |
